Jrsis Health Car Financials
Jrsis Health Car (JRSS) reported $3.5M in revenue for fiscal year 2023, up 159.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2023 cash generation came from an ultra-light asset base, while subscale operations still left the company short of current obligations.
From FY2022 to FY2023, revenue more than doubled and operating margin improved from-51.3% to-5.5% , showing that a larger sales base absorbed overhead far better. Operating cash flow also turned positive to$517K as capital spending fell to maintenance levels, so cash conversion recovered faster than accounting profit even though liquidity stayed tight.
The balance-sheet strain is mostly near-term, not a heavy debt stack: liabilities of
FY2023 still reflects a post-reset company: revenue remained below one-tenth of FY2021, while shares outstanding rose from 18.6M to 82.6M. That combination suggests dilution supplied more of the bridge than new debt, which helps explain why the company could have negative equity without carrying much long-term leverage.
Financial Health Signals
Jrsis Health Car does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Jrsis Health Car scores -0.78, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.5M) relative to total liabilities ($2.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Jrsis Health Car passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Jrsis Health Car reported a net loss of $81K while generating $517K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Jrsis Health Car reported an operating loss of $189K against $56K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Jrsis Health Car generated $3.5M in revenue in fiscal year 2023. This represents an increase of 159.2% from the prior year.
Jrsis Health Car's EBITDA was -$135K in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 80.1% from the prior year.
Jrsis Health Car reported -$81K in net income in fiscal year 2023. This represents an increase of 85.9% from the prior year.
Jrsis Health Car earned $0.00 per diluted share (EPS) in fiscal year 2023. This represents an increase of 88.9% from the prior year.
Cash & Balance Sheet
Jrsis Health Car generated $515K in free cash flow in fiscal year 2023, representing cash available after capex. This represents an increase of 128.5% from the prior year.
Jrsis Health Car held $118K in cash against $25K in long-term debt as of fiscal year 2023, with $2.3M of liabilities due within a year.
Not reported for fiscal year 2023.
Margins & Returns
Jrsis Health Car's gross margin was 14.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is up 40.7 percentage points from the prior year.
Jrsis Health Car's operating margin was -5.5% in fiscal year 2023, reflecting core business profitability. This is up 45.8 percentage points from the prior year.
Jrsis Health Car's net profit margin was -2.3% in fiscal year 2023, showing the share of revenue converted to profit. This is up 40.8 percentage points from the prior year.
Not reported for fiscal year 2023.
Capital Allocation
Jrsis Health Car invested $189K in research and development in fiscal year 2023. This represents a decrease of 33.1% from the prior year.
Jrsis Health Car invested $1K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 96.7% from the prior year.
Not reported for fiscal year 2023.
JRSS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $3.5M+159.2% | $1.3M-97.0% | $44.4M+24.3% | $35.7M+13.5% | $31.5M+10.8% | $28.4M+17.6% | $24.1M+33.3% | $18.1M+52.6% | $11.9M+98.5% | $6.0M+37.4% | $4.4M |
| Cost of Revenue | $3.0M | $3.0M+76.0% | $1.7M | N/A | N/A | N/A | N/A | $7.1M+44.5% | $4.9M+46.6% | $3.3M+92.0% | $1.7M+39.1% | $1.2M |
| Gross Profit | $442K | $483K+235.1% | -$358K | N/A | N/A | N/A | N/A | $17.1M+29.1% | $13.2M+55.0% | $8.5M+101.2% | $4.2M+36.8% | $3.1M |
| R&D Expenses | $133K | $189K-33.1% | $283K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $548K | $336K+18.6% | $283K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$676K | -$189K+72.5% | -$685K-559.7% | -$104K-101.9% | $5.6M+19.8% | $4.7M-22.1% | $6.0M-10.0% | $6.7M+32.5% | $5.0M+91.0% | $2.6M+186.4% | $918K-30.3% | $1.3M |
| Interest Expense | N/A | $56K-12.8% | $65K-95.3% | $1.4M+21.5% | $1.1M+2.3% | $1.1M-1.9% | $1.1M-14.4% | $1.3M-4.3% | $1.4M+11.3% | $1.2M+23.0% | $1.0M+7823.8% | $13K |
| Income Tax | N/A | $9K | N/A | $1.2M-13.8% | $1.4M+108.2% | $658K-76.2% | $2.8M+109300.7% | $3K-37.7% | $4K+55.9% | $3K+20.7% | $2K+8.7% | $2K |
| Net Income | -$490K | -$81K+85.9% | -$576K-118.1% | $3.2M-16.7% | $3.8M+331.0% | $888K-55.4% | $2.0M-57.1% | $4.6M+33.8% | $3.5M+93.9% | $1.8M+192.8% | $611K+52.9% | $400K |
| EPS (Diluted) | — | $0.00+88.9% | -$0.01 | $0.17+16.6% | $0.15 | $0.05-60.3% | $0.13 | N/A | N/A | N/A | $0.05 | $0.29 |
TTM is the trailing twelve months, Q4 FY2023 through Q3 FY2024, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JRSS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1M+5.1% | $2.0M-97.3% | $75.7M+28.7% | $58.8M+13.9% | $51.6M-1.6% | $52.5M+7.8% | $48.7M+53.5% | $31.7M+14.3% | $27.7M+16.2% | $23.9M+28.9% | $18.5M |
| Current Assets | $1.8M+10.2% | $1.7M-88.0% | $13.9M+76.0% | $7.9M-17.2% | $9.5M-20.6% | $12.0M+16.8% | $10.3M+38.3% | $7.4M+76.3% | $4.2M+47.1% | $2.9M+126.0% | $1.3M |
| Cash & Equivalents | $118K+101.5% | $59K+96.4% | $30K-96.5% | $845K-57.1% | $2.0M+668.6% | $256K-71.0% | $884K-0.7% | $891K+152.9% | $352K-66.3% | $1.0M+65.8% | $631K |
| Inventory | $455K-19.0% | $562K-68.3% | $1.8M+21.5% | $1.5M+35.9% | $1.1M-7.8% | $1.2M+24.3% | $937K+16.9% | $801K+60.5% | $499K+176.3% | $181K+83.8% | $98K |
| Accounts Receivable | $715K+4.6% | $683K-90.9% | $7.5M+71.8% | $4.4M-4.2% | $4.6M-44.2% | $8.2M+44.6% | $5.7M+70.3% | $3.3M+66.0% | $2.0M+203.7% | $662K+143.8% | $271K |
| Total Liabilities | $2.3M+9.3% | $2.1M-95.0% | $42.6M+42.1% | $30.0M+4.6% | $28.6M-5.9% | $30.4M+7.0% | $28.4M+42.1% | $20.0M-1.5% | $20.3M+7.7% | $18.9M+22.8% | $15.4M |
| Current Liabilities | $2.3M+8.2% | $2.1M-88.0% | $17.6M+49.7% | $11.8M+7.7% | $10.9M+52.2% | $7.2M+41.2% | $5.1M+57.9% | $3.2M+30.8% | $2.5M-17.3% | $3.0M+748.6% | $351K |
| Long-Term Debt | $25K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$137K-135.1% | -$58K-100.2% | $33.1M+73.9% | $19.0M+28.5% | $14.8M+4.8% | $14.1M+9.6% | $12.9M+94.3% | $6.6M+79.9% | $3.7M+85.0% | $2.0M+320.8% | $474K |
| Retained Earnings | -$3.4M-2.4% | -$3.4M-79.1% | -$1.9M+54.3% | -$4.1M+39.5% | -$6.8M-152.6% | $12.9M+18.2% | $10.9M+74.1% | $6.3M+123.9% | $2.8M+177.0% | $1.0M+152.9% | $400K |
Not reported in any period shown, so not listed: Goodwill.
JRSS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$730K | $517K+129.3% | -$1.8M-121.4% | $8.2M-22.6% | $10.6M-10.2% | $11.8M+28.8% | $9.2M+10.3% | $8.3M+67.2% | $5.0M+97.0% | $2.5M+23.2% | $2.1M+106.8% | $993K |
| Capital Expenditures | N/A | $1K-96.7% | $45K-98.1% | $2.3M-72.1% | $8.3M+75.5% | $4.7M+43.8% | $3.3M+26.5% | $2.6M-25.5% | $3.5M-32.6% | $5.2M+43.4% | $3.6M+412.2% | $702K |
| Free Cash Flow | N/A | $515K+128.5% | -$1.8M-130.5% | $5.9M+150.0% | $2.4M-66.8% | $7.1M+20.5% | $5.9M+3.0% | $5.7M+280.4% | $1.5M+157.6% | -$2.6M-70.4% | -$1.5M-627.6% | $292K |
| Investing Cash Flow | N/A | $19K+100.7% | -$2.8M+48.6% | -$5.5M+33.5% | -$8.3M-108.7% | -$4.0M+33.6% | -$6.0M+55.7% | -$13.5M-272.9% | -$3.6M | N/A | N/A | N/A |
| Financing Cash Flow | $728K | -$568K-130.6% | $1.9M+166.4% | -$2.8M+18.4% | -$3.4M+43.9% | -$6.1M-55.7% | -$3.9M-175.9% | $5.2M+765.9% | -$776K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2023 through Q3 FY2024, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
JRSS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.0%+40.7pp | -26.8% | N/A | N/A | N/A | N/A | 70.8%-2.3pp | 73.0%+1.1pp | 71.9%+1.0pp | 71.0%-0.3pp | 71.3% |
| Operating Margin | -5.5%+45.8pp | -51.3%-51.1pp | -0.2%-15.9pp | 15.7%+0.8pp | 14.8%-6.3pp | 21.1%-6.5pp | 27.6%-0.2pp | 27.7%+5.6pp | 22.1%+6.8pp | 15.3%-14.9pp | 30.3% |
| Net Margin | -2.3%+40.8pp | -43.1%-50.3pp | 7.2%-3.5pp | 10.7%+7.9pp | 2.8%-4.2pp | 7.0%-12.2pp | 19.2%+0.1pp | 19.2%+4.1pp | 15.1%+4.8pp | 10.2%+1.0pp | 9.2% |
| Return on Equity | N/A | N/A | 9.6%-10.5pp | 20.1%+14.1pp | 6.0%-8.1pp | 14.1%-21.9pp | 36.0%-16.3pp | 52.3%+3.8pp | 48.6%+17.9pp | 30.7%-53.7pp | 84.4% |
| Return on Assets | -3.8%+24.4pp | -28.2%-32.4pp | 4.2%-2.3pp | 6.5%+4.8pp | 1.7%-2.1pp | 3.8%-5.8pp | 9.6%-1.4pp | 10.9%+4.5pp | 6.5%+3.9pp | 2.6%+0.4pp | 2.2% |
| Current Ratio | 0.800.0x | 0.790.0x | 0.79+0.1x | 0.67-0.2x | 0.87-0.8x | 1.67-0.3x | 2.02-0.3x | 2.31+0.6x | 1.71+0.7x | 0.96-2.6x | 3.61 |
| Debt-to-Equity | N/A | N/A | 1.29-0.3x | 1.57-0.4x | 1.93-0.2x | 2.15-0.1x | 2.21-0.8x | 3.02-2.5x | 5.51-4.0x | 9.47-23.0x | 32.45 |
| FCF Margin | 14.9% | -135.5% | 13.4%+6.7pp | 6.6%-16.0pp | 22.7%+1.8pp | 20.8%-2.9pp | 23.8%+15.5pp | 8.3%+30.4pp | -22.1%+3.7pp | -25.7%-32.4pp | 6.7% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: FCF Margin.
Note: Shareholder equity is negative (-$137K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Jrsis Health Car Ranks
Frequently Asked Questions
What is Jrsis Health Car's annual revenue?
Jrsis Health Car (JRSS) reported $3.5M in total revenue for fiscal year 2023. This represents a 159.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Jrsis Health Car's revenue growing?
Jrsis Health Car (JRSS) revenue grew by 159.2% year-over-year, from $1.3M to $3.5M in fiscal year 2023.
Is Jrsis Health Car profitable?
No, Jrsis Health Car (JRSS) reported a net income of -$81K in fiscal year 2023, with a net profit margin of -2.3%.
What is Jrsis Health Car's EBITDA?
Jrsis Health Car (JRSS) had EBITDA of -$135K in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Jrsis Health Car have?
As of fiscal year 2023, Jrsis Health Car (JRSS) had $118K in cash and equivalents against $25K in long-term debt.
What is Jrsis Health Car's gross margin?
Jrsis Health Car (JRSS) had a gross margin of 14.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Jrsis Health Car's operating margin?
Jrsis Health Car (JRSS) had an operating margin of -5.5% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Jrsis Health Car's net profit margin?
Jrsis Health Car (JRSS) had a net profit margin of -2.3% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Jrsis Health Car's free cash flow?
Jrsis Health Car (JRSS) generated $515K in free cash flow during fiscal year 2023. This represents a 128.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Jrsis Health Car's operating cash flow?
Jrsis Health Car (JRSS) generated $517K in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Jrsis Health Car's total assets?
Jrsis Health Car (JRSS) had $2.1M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Jrsis Health Car's capital expenditures?
Jrsis Health Car (JRSS) invested $1K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Jrsis Health Car spend on research and development?
Jrsis Health Car (JRSS) invested $189K in research and development during fiscal year 2023.
What is Jrsis Health Car's current ratio?
Jrsis Health Car (JRSS) had a current ratio of 0.80 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Jrsis Health Car's return on assets (ROA)?
Jrsis Health Car (JRSS) had a return on assets of -3.8% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
Why is Jrsis Health Car's debt-to-equity ratio negative or not reported?
Jrsis Health Car (JRSS) has negative shareholder equity of -$137K as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Jrsis Health Car's Altman Z-Score?
Jrsis Health Car (JRSS) has an Altman Z-Score of -0.78, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Jrsis Health Car's Piotroski F-Score?
Jrsis Health Car (JRSS) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Jrsis Health Car's earnings high quality?
Jrsis Health Car (JRSS) reported a net loss of $81K while generating $517K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Jrsis Health Car cover its interest payments?
Jrsis Health Car (JRSS) reported an operating loss of $189K against $56K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.